# A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

> **NCT07664735** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Outpace Bio, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Endometrial Cancer Recurrent
- Endometrial Cancer
- Advanced Endometrial Cancer
- Ovarian Cancer
- Ovarian Cancer Recurrent
- Platinum Resistant Ovarian Cancer
- Endometrial Cancers

## Interventions

- **BIOLOGICAL:** OPB-201

## Key facts

- **NCT ID:** NCT07664735
- **Lead sponsor:** Outpace Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2030-06
- **Final completion:** 2030-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664735, "A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07664735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*